UNSPSC 51123206: Mexiletine hydrochloride

This classification denotes an antiarrhythmic agent with the molecular formula C11H17NO.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 606D60IS38, chemically known as 2-propanamine, 1-(2,6-dimethylphenoxy)-, hydrochloride but more generally known as mexiletine hydrochloride, which bears US NIH Compound Identifier 21467. European Medicines Agency schedules Mexiletine hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03281MIG.

Most nations, for tariff and trade purposes, schedule mexiletine hydrochloride under HS 29221980 and SITC 51461. As of Q4 2014, MEXILETINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Mexiletine hydrochloride bears US NLM identifiers UMLS ID C0600129 and NCI Concept Code C652. SMILES: CC1CCCC(C1OCC(C)N)C.CL.

UNSPSC 51123206 Mexiletine hydrochloride, a Commodity code, identifies a specific antiarrhythmic medication that state and local governments procure as part of broader emergency-response and pharmacy-benefit programs. Recent solicitations show state and local buyers acquiring this product through two distinct channels: emergency medical services (EMS) purchasing mexiletine alongside other advanced life support medications, and state health agencies sourcing it through cooperative purchasing vehicles that aggregate generic pharmaceutical demand across multiple jurisdictions. The work involves supplying pharmaceuticals with strict expiration-date requirements (typically nine months or more from acceptance), maintaining cold-chain or stability compliance, providing comprehensive safety documentation per OSHA standards, and meeting FDA manufacturing and labeling requirements. Issuing bodies include municipal fire and rescue departments, state health and human services agencies, and multistate cooperative purchasing alliances that coordinate procurement for participating state and local government facilities.

Recent activity spans Florida, Texas, and Minnesota. The City of Tampa's Purchasing Department issued an IFB (Bid No. 26-P-00188) in April 2026 for Advanced Life Support Medications to be used by Tampa Fire Rescue, requiring delivery within ten calendar days, with an estimated contract value of $40,000 and a one-year term plus optional renewals; the bid was sheltered with a 5 percent SLBE discount. The Texas Health and Human Services Commission issued a Request for Information in April 2026 exploring direct-to-manufacturer prescription programs as a preliminary step toward formal procurement. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) issued an RFP in January 2026 for generic multi-source pharmaceuticals and OTC products, with responses due March 26, 2026 and contract effectiveness July 1, 2026, requiring vendors to work through three authorized wholesalers (AmerisourceBergen/Cencora, Cardinal Health, and Morris & Dickson) and to comply with cGMP and Drug Supply Chain Security Act standards. Municipal emergency services and state pharmacy programs dominate the recent issuing-body mix.